Gainers

• Azitra (AMEX:AZTR) stock rose 52.6% to $0.27 during Friday's regular session. The company's market cap stands at $1.8 million.
• Dermata Therapeutics (NASDAQ:DRMA) shares increased by 40.5% to $1.7. The market value of their outstanding shares is at $3.4 million.
• Baird Medical Investment (NASDAQ:BDMD) stock increased by 26.21% to $2.15. The company's market cap stands at $62.4 million.
• Lunai Bioworks (NASDAQ:LNAI) shares rose 22.64% to $0.47. The company's market cap stands at $9.3 million.
• Mobile-health Network (NASDAQ:MNDR) stock rose 21.62% to $1.18. The company's market cap stands at $3.5 million.
• CapsoVision (NASDAQ:CV) shares rose 17.06% to $7.23. The company's market cap stands at $289.4 million.

Losers

• Milestone Pharmaceuticals (NASDAQ:MIST) shares fell 17.5% to $1.4 during Friday's regular session. The market value of their outstanding shares is at $144.7 million. As per the news, the Q4 earnings report came out today.
• Silexion Therapeutics (NASDAQ:SLXN) stock declined by 12.43% to $1.26. The market value of their outstanding shares is at $4.4 million. As per the press release, Q4 earnings came out 3 days ago.
• NexGel (NASDAQ:NXGL) shares declined by 12.16% to $0.68. The company's market cap stands at $6.3 million.
• Zhengye Biotechnology (NASDAQ:ZYBT) stock decreased by 11.33% to $0.97. The market value of their outstanding shares is at $51.6 million.
• Nutriband (NASDAQ:NTRB) stock declined by 11.14% to $3.51. The market value of their outstanding shares is at $48.0 million.
• Aardvark Therapeutics (NASDAQ:AARD) stock declined by 10.82% to $4.37. The market value of their outstanding shares is at $106.6 million. See Also: www.benzinga.com/money/best-healthcare-stocks/

This article was generated by Benzinga's automated content engine and reviewed by an editor.

Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.